Because ED‐B is specifically present in the tumour microenvironment, its targeting presents a promising therapeutic option for the delivery of therapeutic agents, such as cytokines, chemotherapeutics, cytotoxic agents and radioisotopes, to tumours (Kumra and Reinhardt, 2016). The gene discussed is FN1; the disease is neoplasm.